Trung Huynh
Stock Analyst at UBS
(4.84)
# 60
Out of 5,067 analysts
56
Total ratings
73.68%
Success rate
34.14%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Trung Huynh
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| REGN Regeneron Pharmaceuticals | Maintains: Neutral | $595 → $660 | $761.45 | -13.32% | 5 | Nov 7, 2025 | |
| LLY Eli Lilly and Company | Maintains: Buy | $895 → $1,080 | $1,070.16 | +0.92% | 10 | Nov 7, 2025 | |
| INSM Insmed | Maintains: Buy | $194 → $223 | $206.93 | +7.77% | 9 | Oct 31, 2025 | |
| JSPR Jasper Therapeutics | Maintains: Buy | $29 → $25 | $1.72 | +1,353.49% | 3 | Aug 15, 2025 | |
| AMGN Amgen | Maintains: Neutral | $326 → $317 | $334.30 | -5.17% | 6 | Aug 6, 2025 | |
| CLDX Celldex Therapeutics | Maintains: Buy | $44 → $38 | $26.36 | +44.16% | 2 | May 9, 2025 | |
| PFE Pfizer | Maintains: Neutral | $24 → $25 | $25.22 | -0.87% | 6 | Apr 30, 2025 | |
| BMY Bristol-Myers Squibb Company | Maintains: Neutral | $60 → $54 | $47.76 | +13.07% | 5 | Apr 11, 2025 | |
| CABA Cabaletta Bio | Maintains: Buy | $10 → $7 | $2.30 | +204.35% | 2 | Apr 1, 2025 | |
| KYTX Kyverna Therapeutics | Initiates: Buy | $13 | $7.50 | +73.40% | 1 | Oct 10, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $170 → $175 | $206.05 | -15.07% | 2 | Jul 21, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $125 → $126 | $100.40 | +25.50% | 3 | Mar 7, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $170 | $229.51 | -25.93% | 1 | Nov 18, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Outperform | n/a | $8.38 | - | 1 | Mar 23, 2021 |
Regeneron Pharmaceuticals
Nov 7, 2025
Maintains: Neutral
Price Target: $595 → $660
Current: $761.45
Upside: -13.32%
Eli Lilly and Company
Nov 7, 2025
Maintains: Buy
Price Target: $895 → $1,080
Current: $1,070.16
Upside: +0.92%
Insmed
Oct 31, 2025
Maintains: Buy
Price Target: $194 → $223
Current: $206.93
Upside: +7.77%
Jasper Therapeutics
Aug 15, 2025
Maintains: Buy
Price Target: $29 → $25
Current: $1.72
Upside: +1,353.49%
Amgen
Aug 6, 2025
Maintains: Neutral
Price Target: $326 → $317
Current: $334.30
Upside: -5.17%
Celldex Therapeutics
May 9, 2025
Maintains: Buy
Price Target: $44 → $38
Current: $26.36
Upside: +44.16%
Pfizer
Apr 30, 2025
Maintains: Neutral
Price Target: $24 → $25
Current: $25.22
Upside: -0.87%
Bristol-Myers Squibb Company
Apr 11, 2025
Maintains: Neutral
Price Target: $60 → $54
Current: $47.76
Upside: +13.07%
Cabaletta Bio
Apr 1, 2025
Maintains: Buy
Price Target: $10 → $7
Current: $2.30
Upside: +204.35%
Kyverna Therapeutics
Oct 10, 2024
Initiates: Buy
Price Target: $13
Current: $7.50
Upside: +73.40%
Jul 21, 2023
Maintains: Neutral
Price Target: $170 → $175
Current: $206.05
Upside: -15.07%
Mar 7, 2023
Maintains: Outperform
Price Target: $125 → $126
Current: $100.40
Upside: +25.50%
Nov 18, 2022
Initiates: Outperform
Price Target: $170
Current: $229.51
Upside: -25.93%
Mar 23, 2021
Upgrades: Outperform
Price Target: n/a
Current: $8.38
Upside: -